Experimental drug cuts Parkinson's-linked protein up to 60% in early trial
medicalxpress - An experimental drug designed to silence a gene strongly linked to Parkinson's disease has shown encouraging effects in a first-in-human clinical trial, according to a study published in Nature Medicine. The drug, known as BIIB094, targets LRRK2, the most…
AI Summary: An experimental therapeutic cut levels of a Parkinson’s‑linked protein by up to 60% in an early human study, while complementary preclinical work identified a compound that clears toxic Parkinson’s proteins from brain tissue. The twin findings hint at disease‑modifying potential, though meaningful clinical benefit and long‑term safety remain to be demonstrated.
Related Stories
First-in-human trial primes immune system to accept donor livers / 2 months
Drug-induced hibernation shows promise to limit stroke brain injury / 21 days
BioMarin Phase 3 failure dims hopes for rare‑disease therapy / 7 wks
Insmed shelves Brinsupri in skin indication after mid‑stage flop / 3 months
Sanofi ousts Paul Hudson as Belén Garijo named incoming CEO / 4 months
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 7 days
Teclistamab shows survival benefit prompting earlier use discussions / 21 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Adolescent Health, Cancer Screening, Biotech, Research Funding and look for the RSS link.
StackHealth Time Machine